Aquestive Therapeutics Files 8-K

Ticker: AQST · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateSep 9, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: AQST

TL;DR

AQST filed an 8-K, likely routine financial updates.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on September 9, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.

Why It Matters

This filing indicates routine corporate reporting, including financial updates and disclosures, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — The filing appears to be a standard current report with no immediately apparent significant negative or positive events disclosed.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • MonoSol Rx, Inc. (company) — Former company name
  • September 9, 2024 (date) — Date of report
  • 30 Technology Drive Warren, NJ 07059 (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

When was the report filed?

The report was filed on September 9, 2024.

What is the principal executive office address of Aquestive Therapeutics, Inc.?

The principal executive office address is 30 Technology Drive, Warren, NJ 07059.

What was Aquestive Therapeutics, Inc.'s former company name?

Aquestive Therapeutics, Inc.'s former company name was MonoSol Rx, Inc.

In which state is Aquestive Therapeutics, Inc. incorporated?

Aquestive Therapeutics, Inc. is incorporated in Delaware.

Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-09-09 08:56:17

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. Copies of the Company's investor presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. A copy of the Company's investor presentation given to investors, analysts an others at the H.C. Wainwright 26th Annual Global Investor Conference on September 9, 2024 is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The H.C. Wainwright presentation is available on the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Corporate Presentation dated September 2024 99.2 Aquestive Therapeutics, Inc. H.C. Wainwright 26th Annual Global Investor Conference Presentation dated September 9, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 9, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.